Best Brazos County Grants for Nonprofits in Texas

Investigating the Benefit of Early Treatment with Ritlecitinib in Alopecia Areata: A Real-World Evidence Approach

Alopecia Areata (AA) is a chronic, immune-mediated condition causing nonscarring hair loss that affects about 2% of the global population and can lead to substantial psychosocial burden if disease is severe and untreated. The treatment landscape has recently evolved with the approval of ritlecitinib, a systemic therapy for severe AA in adults and adolescents aged 12 years and older, based on efficacy demonstrated in the ALLEGRO phase 2b/3 program.

Despite this advance, important questions remain regarding the optimal timing of therapy initiation. Emerging post-hoc analyses from the ALLEGRO program indicate that patients with shorter disease duration and lower baseline severity achieve higher response rates, suggesting that earlier intervention with ritlecitinib may lead to improved outcomes.

Geographic Scope

United States 

Funding Range and Project Length

Individual projects requesting up to $100,000 USD will be considered.

Maximum project length is 24 months.

Hemophilia Fellowship

This competitive grant program seeks to support an institution-based fellowship that emphasizes shared decision making (SDM), patient education, and multidisciplinary team-based care. The intent is to strengthen the hemophilia care through equitable education, and patient-centered shared decision making in a rapidly evolving treatment landscape.

Geographic Scope

• United States 

Funding Range and Project Length

• Grant funding is available to support a one year fellowship up to $100.000 USD. 

Accelerating the Development of Combined CGM–Pump Devices

A combined continuous glucose monitor (CGM) and insulin pump device represents an innovative approach to simplifying diabetes management by integrating two essential technologies into a single device. This approach has the potential to improve quality of life for people with type 1 diabetes (T1D) by reducing the burden associated with wearing and managing multiple devices.

Despite this promise, the development of combined CGM–pump devices presents technical and commercialization challenges. These include the need for further advances in device compatibility and lifespan, system reliability, and scalable manufacturing, while maintaining affordability and broadaccessibility. In addition, a potential insulin dilution effect may require adjustment of the CGM algorithm.

Breakthrough T1D invites applications for research and development projects that address key technical, clinical, and translational challenges related to combined CGM–pump devices, with the goal of accelerating their development and improving outcomes for people living with T1D.

In response to this announcement, applications may request up to a total of $900,000 USD for up to three years.